Recently added

Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes

Celada, Lucía; RUIZ-CANTADOR, JOSE; da Silva Alves Pereira, Bianca Gabriela; Iglesias Felip, Carmela; Casteràs, Anna; Arenillas, Carlota; Calsina, Bruna; Datta, Debayan; García-Galea, Eduardo; fasani, roberta; Moreno-Cárdenas, Ana Belén; Miranda, Berta; Dienstmann, Rodrigo; Villanueva Cardús, Josep; Capdevila Castillon, Jaume; Nuciforo, Paolo; DOS SUBIRA, LAURA; Toledo, Rodrigo (American Association for Cancer Research, 2025-05-01)

Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy

Chiang, A. C.; Carlisle, Jennifer Wilkinson; Reguart, Noemi; Olmedo García, María Eugenia; Dowlati, Afshin; FELIP, ENRIQUETA (Elsevier, 2025-04)

In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC

Muhl, Lars; Hellberg, Louise; Artursson, Rebecca; Friedrich, Jakob; Lindberg, Amanda; Mezheyeuski, Artur; Yu, Hui (Elsevier, 2025-05)

A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)

Pubul Núñez, Virginia; Anido Herranz, Urbano; Walter, Thomas; Hernando, Jorge; Garcia-Alvarez, Alejandro; Capdevila Castillon, Jaume; Molina-Cerrillo, Javier; Alonso-Gordoa, Teresa; Garcia-Burillo, Amparo; Villacampa Javierre, Guillermo (BMC, 2025-04-04)

A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers

Gallagher, Peter; Rolfo, Christian; Elez, Elena; Houlden, Jennifer; Collins, Linda; taieb, julien; Tabernero, Josep (Nature Portfolio, 2025-03-26)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes

Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy

In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC

A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)

A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes ﻿

Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy ﻿

In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC ﻿

A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217) ﻿

A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers ﻿

Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes

Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy

In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC

A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)

A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers